← Back to Search

Neural Stimulation

Neural Stimulation for Schizophrenia

N/A
Waitlist Available
Research Sponsored by The University of Texas at Dallas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change in daily expectations of social interactions will be assessed from the pre-stimulation ema period (7 days before the stimulation visit) to the post-stimulation ema period (7 days after the stimulation visit)
Awards & highlights

Summary

This trial will assess whether stimulating the brain can improve symptoms & functioning in people with schizophrenia-like disorders.

Who is the study for?
This trial is for adults aged 18-60 with schizophrenia or schizoaffective disorder experiencing recent paranoia. It's not suitable for pregnant individuals, those with certain developmental disorders, neurological conditions like epilepsy, active substance use disorders, severe sensory impairments, a history of electroconvulsive therapy, non-English speakers, or anyone with implanted medical devices.
What is being tested?
The study investigates if brain stimulation through transcranial Direct Current Stimulation (tDCS) can alleviate psychotic symptoms and improve social functioning in people with schizophrenia spectrum disorders.
What are the potential side effects?
Potential side effects of tDCS may include discomfort at the electrode site on the scalp, itching or tingling during stimulation, fatigue after treatment sessions, headache or nausea.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change in daily paranoia feelings will be assessed from the pre-stimulation ema period (7 days before the stimulation visit) to the post-stimulation ema period (7 days after the stimulation visit)
This trial's timeline: 3 weeks for screening, Varies for treatment, and change in daily paranoia feelings will be assessed from the pre-stimulation ema period (7 days before the stimulation visit) to the post-stimulation ema period (7 days after the stimulation visit) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Paranoid Ideation for Active vs. Sham Stimulation
Social functioning for Active vs. Sham Stimulation

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active anodal tDCS first, then Sham tDCSExperimental Treatment1 Intervention
Active anodal tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing; Washout (about 1 week); sham stimulation (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing.
Group II: Sham tDCS first, then Active anodal tDCSPlacebo Group1 Intervention
Sham tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing; Washout (about 1 week); Active anodal tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing Intervention.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
tDCS
2017
Completed Phase 2
~640

Find a Location

Who is running the clinical trial?

The University of Texas at DallasLead Sponsor
62 Previous Clinical Trials
106,594 Total Patients Enrolled

Media Library

tDCS (Neural Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05746494 — N/A
Schizoaffective Disorder Research Study Groups: Active anodal tDCS first, then Sham tDCS, Sham tDCS first, then Active anodal tDCS
Schizoaffective Disorder Clinical Trial 2023: tDCS Highlights & Side Effects. Trial Name: NCT05746494 — N/A
tDCS (Neural Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05746494 — N/A
~18 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top